Gufic BioSciences Complete Financial Statements
In FY2026, Gufic BioSciences (GUFICBIO) reported revenue ₹251 Cr, net profit ₹22 Cr and EPS ₹2.18, with a net profit margin of 8.8% and ROE of 3.3%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse GUFICBIO institutional holdings to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GUFICBIO Revenue, Net Profit & EBITDA — Year-on-Year Growth
GUFICBIO YoY (Mar 2025 vs Mar 2026) — revenue +22.4%, net profit +175.0%, EBITDA +70.4%, expenses +14.5%. Examine GUFICBIO earnings for recent quarterly revenue, profit and EPS trends.
GUFICBIO Income Statement — Revenue, EBITDA & Net Profit
Gufic BioSciences revenue ₹251 Cr, EBITDA ₹46 Cr, net profit ₹22 Cr, EPS ₹2.18 (2026) — net profit margin 8.8%. For live price, earnings ratios and company overview, see GUFICBIO screener.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Jun 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 251 | 239 | 205 | 225 | 232 | 204 | 196 | 204 | 210 | 215 | 196 | 202 |
| Expenses | 205 | 199 | 179 | 190 | 198 | 166 | 161 | 167 | 174 | 176 | 159 | 165 |
| EBITDA | 46 | 40 | 27 | 34 | 34 | 39 | 35 | 37 | 36 | 40 | 36 | 37 |
| Operating Profit Margin % | 19.00% | 16.00% | 13.00% | 15.00% | 14.00% | 19.00% | 18.00% | 18.00% | 16.00% | 18.00% | 18.00% | 18.00% |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 |
| Interest | 9 | 10 | 8 | 9 | 8 | 5 | 4 | 5 | 5 | 5 | 4 | 3 |
| Profit Before Tax | 29 | 23 | 11 | 17 | 18 | 29 | 27 | 28 | 26 | 31 | 28 | 30 |
| Tax | 7 | 6 | 3 | 4 | 5 | 8 | 7 | 7 | 7 | 8 | 7 | 7 |
| Net Profit | 22 | 17 | 8 | 13 | 12 | 22 | 20 | 21 | 19 | 23 | 21 | 22 |
| Earnings Per Share (₹) | 2.18 | 1.68 | 0.77 | 1.30 | 1.24 | 2.17 | 2.00 | 2.08 | 1.93 | 2.39 | 2.13 | 2.23 |
GUFICBIO Balance Sheet — Assets, Liabilities & Shareholders' Equity
GUFICBIO total assets ₹1,342 Cr, total equity ₹665 Cr, total liabilities ₹ Cr (2026) — ROE 3.3%.
| Particulars | 2026 | 2025 | 2024 |
|---|---|---|---|
| ASSETS | |||
| Total Assets | 1,342 | 1,169 | 1,093 |
| Current Assets | 802 | 625 | 601 |
| Fixed Assets | 513 | 506 | 159 |
| Capital Work in Progress | 22 | 22 | 307 |
| Investments | 325 | 2 | 2 |
| Other Assets | 0 | 640 | 625 |
| LIABILITIES | |||
| Total Liabilities | |||
| Current Liabilities | 160 | 181 | 188 |
| Non-Current Liabilities | |||
| SHAREHOLDERS' EQUITY | |||
| Total Equity | 665 | 601 | 533 |
| Share Capital | 10 | 10 | 10 |
| Reserves & Surplus | 655 | 591 | 523 |
GUFICBIO Cash Flow Statement — Operating, Investing & Financing
Gufic BioSciences operating cash flow ₹123 Cr, investing ₹-71 Cr, financing ₹-37 Cr, net cash flow ₹15 Cr (2025).
| Particulars | March 2025 | March 2024 |
|---|---|---|
| Operating Activities | 123 | -8 |
| Investing Activities | -71 | -102 |
| Financing Activities | -37 | 82 |
| Net Cash Flow | 15 | -28 |